IL-23IL-23

Back to Disease

What is the Efficacy of Guselkumab Across the GRAPPA Domains?

Long-Term Guselkumab Safety in Psoriasis & PsA (Phase II/III Analysis)

How do IL-23 and IL-17 Inhibitors Differ in Clinical Efficacy

What Is the Safety Profile of Guselkumab in PsO and PsA?

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

How Is Guselkumab Dosed in PsO, PsA, and IBD?

How Do You Interpret cDAPSA/DAPSA and MDA?

Data Review From the Phase III DISCOVER-2 Trials

Differentiation of Therapeutic Antibodies Targeting Interleukin (IL)-23

How Does Real-World Evidence Differ From Randomized Controlled Trials?

sectionimg

dotsimg

Download the app and start using it now.

Download on the App Store

GET IT ON Google Play